Zomig
Product Images NDC 21695-955

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Zomig (NDC 21695-955). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (F2073122 5138 41ba B791 A9b088bb98b7 01)

Chemical structure diagram of the active ingredient in ZOMIG, depicting the molecular arrangement including an indole ring system and a dimethylaminoethyl side chain.*

FDA Label Image

Figure One Graph (F2073122 5138 41ba B791 A9b088bb98b7 02)

A line graph titled 'Estimated probability of achieving an initial headache response within 4 hours of initial treatment' comparing 5.0 mg nasal spray versus placebo. The x-axis represents hours since initial dose (0 to 4), while the y-axis shows the estimated probability of response in percentage (0 to 100). The 5.0 mg nasal spray line shows a higher and increasing response rate over time compared to placebo.*

FDA Label Image

Figure Two Graph (F2073122 5138 41ba B791 A9b088bb98b7 03)

A line graph showing the estimated probability of patients taking an escape medication within 24 hours after the initial dose of treatment. Two groups are compared: one receiving a 5.0 mg nasal spray represented by squares, and a placebo group represented by triangles. The y-axis shows the probability percentage from 0 to 100, and the x-axis indicates hours since the initial dose from 0 to 24.*

FDA Label Image

Figure 1 (F2073122 5138 41ba B791 A9b088bb98b7 04)

Instructional illustration labeled 'Figure 1' showing a hand holding the black elongated component of a ZOMIG nasal spray device being positioned with an arrow indicating to connect or assemble it to a white nasal applicator part held in the other hand.*

FDA Label Image

Figure 2 (F2073122 5138 41ba B791 A9b088bb98b7 05)

An instructional illustration labeled Figure 2 showing a hand holding a small, black, cylindrical object with a pointed tip, featuring labeled parts A, C, and D. The image appears to demonstrate how to hold or use the object, likely related to ZOMIG product application or administration.*

FDA Label Image

Figure 3 (F2073122 5138 41ba B791 A9b088bb98b7 06)

An instructional illustration labeled Figure 3 showing a woman demonstrating a technique by inserting her finger into her nostril, possibly related to nasal administration or usage instructions for ZOMIG, a migraine treatment by Rebel Distributors Corp.*

FDA Label Image

Figure 4 (F2073122 5138 41ba B791 A9b088bb98b7 07)

An instructional illustration showing a woman administering a nasal spray medication using a nasal spray device. She holds the device in one hand and inserts it into one nostril while using her other hand to press the opposite nostril closed.*

FDA Label Image

Zomig 5mg (F2073122 5138 41ba B791 A9b088bb98b7 08)

Label for Zomig 5mg nasal spray, a prescription medication containing zolmitriptan. The label includes the Physician Partner logo, the NDC 21695-955-06, and instructions indicating each single-use nasal spray delivers 5mg zolmitriptan. It states the product is manufactured by AstraZeneca UK Limited in Cheshire, UK, and distributed by Physician Partner in Thousand Oaks, California. Additional information includes storage conditions and a warning to keep the medication out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.